CMA opens bipolar drug probe

The UK’s antitrust authority has launched an abuse of dominance investigation into Essential Pharma after the drugmaker threatened to withdraw a lithium-based bipolar disorder medication from the market.


Get unlimited access to all Global Competition Review content